Healthtech Startups

NeoCannBio is a technology spin-off from KIST developing cannabinoid-based pharmaceuticals and producing hemp-derived cannabinoid drug ingredients, including high-purity CBD via microwave processing and GMP production. The company builds a broad cannabinoid library and develops new drugs for patients with rare and intractable diseases in Korea.

1 investor

Novelty Nobility develops antibody and protein therapeutics for clinical applications. The company's leadership team brings expertise in immunization, affinity maturation, and biopharmaceutical development across therapeutic areas including ophthalmology.

1 investor

Deep Bio is a medical AI company that develops cancer diagnostic software using deep learning technology. The company conducts clinical trials on its medical devices and plans to commercialize products in domestic and international biotech markets.

1 investor

Renhaim is a biotechnology company developing advanced RNA-based pharmaceuticals, including cancer therapeutics, preventive vaccines, and gene/cell therapies for unmet medical needs.

1 investor

LigaChemBio is a biotechnology company focused on drug development, particularly in ADC (antibody-drug conjugate) and small molecule therapeutics. The company develops and partners on therapeutic pipelines for pharmaceutical applications.

1 investor

MicrobiotiX develops bacteriophage-based therapeutics targeting multi-drug resistant bacterial infections, including WHO/CDC priority pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and E. coli. The company operates a phage discovery and development platform with a library of about 1,000 bacteriophages, in-silico modules, and GMP production facilities, and its lead pipeline MP101 has entered clinical trials with first-patient-in completed.

1 investor

MEPSGEN develops microphysiological systems (MPS) and organ-on-chip technologies for drug development and testing, serving pharmaceutical companies and contract research organizations. The company manufactures nanoparticles and microspheres, produces automated robotic systems for MPS modeling, and develops nanomedicines for diseases including glioblastoma and Alzheimer's disease.

1 investor

Based on the partner page listing major Korean hospitals, pharmaceutical firms, and international biotech institutions, the company appears to operate in healthcare or biotech, but the page does not explicitly state the company's core business or customer focus.

1 investor

Bibros operates DDocDoc (똑닥), a mobile app for booking and checking in for hospital and clinic appointments in South Korea. The company serves patients seeking to schedule medical visits.

1 investor

Cellebrain is a biotech company developing stem cell-based gene therapies for intractable diseases that currently lack pharmacological treatments. It focuses on gene-cell therapies aimed at improving the quality of life for patients with cancer and chronic diseases.

1 investor

CDMOgen (씨드모젠) is a contract development and manufacturing organization specializing in viral vector- and mRNA-based gene therapies and vaccines, offering CDO, CMO, and CRO services including GMP manufacturing and quality/analytical testing. It serves biopharmaceutical developers and was the first in South Korea to receive GMP manufacturing approval for gene therapy products.

1 investor

Avixgen develops therapeutic treatments for ophthalmological diseases such as macular degeneration and dry eye, inflammatory conditions including atopic dermatitis, and an in-house drug delivery platform called ACP technology.

1 investor

FNCT Biotech is a biotech company based in South Korea. The page provides limited information about the company's specific products or services beyond its investment and program participation history.

1 investor

Exostemtech develops stem cell-derived exosome therapeutics and exosome platforms, including plant-derived exosomes, and offers research-use materials such as research stem cells and exosomes. The company operates in the biotechnology sector with a focus on exosome-based drug development.

1 investor

Endovision develops and manufactures medical devices including wound care, tissue regeneration, spinal surgery, sports medicine, gynecology, and laparoscopy products for hospitals and healthcare providers. The company, founded in 2013, focuses on domestic medical device innovation with capabilities in biotech products, 3D printing, and veterinary medical devices.

1 investor

NKMAX (엔케이젠바이오텍코리아 / NKGen Biotech Korea) is an immune cell therapy company focused on Natural Killer (NK) cells, developing NK-based immunotherapies, precision immune testing (NK cell activity tests), and immune health functional foods. Its products include NK cell activity diagnostic testing and the NK365 immune-support health supplement.

1 investor

Okchundang is a Korean herbal medicine (한의원) service provider operated by licensed Korean medicine doctors, offering distribution, herbal decoction (탕전) extraction and delivery systems for oriental medicine clinics. It also runs an hGMP-certified pharmaceutical arm supplying medicinal herbs and shares clinical academic information for practitioners.

1 investor

U2medtek develops SinusView, a near-infrared imaging device with AI algorithms for non-invasive, radiation-free diagnosis of sinusitis in clinical settings. The Class II certified medical device enables real-time visualization and automated analysis of sinus conditions for ENT and primary care clinicians.

1 investor

EHLBIO develops stem cell therapeutics and works in regenerative medicine, including an autologous adipose-derived stem cell treatment (ADSTEM) for conditions such as atopic dermatitis. The company is based in South Korea and its therapies are progressing through clinical trials with the Korean Ministry of Food and Drug Safety.

1 investor

GB SOFT develops AI software that measures vital signs — such as pulse, oxygen saturation, and stress levels — through contactless camera-based technology on smart devices. Its digital healthcare applications span wellness, industrial safety, autonomous mobility, and remote medical care.

1 investor

GLPharmTech is a pharmaceutical company that develops modified-release drug formulations, including Kabalin CR (pregabalin extended-release), for treating neuropathic pain conditions such as diabetic peripheral neuropathy and postherpetic neuralgia.

1 investor

Zincure is a biotech company developing treatments for brain disorders, focusing on acute conditions such as stroke and neurodegenerative diseases including ALS and multiple sclerosis. Founded in 2020, it conducts preclinical drug development in collaboration with hospitals and universities in Korea and the US.

1 investor

Kolon Pharmaceuticals develops pharmaceuticals and runs an oncology drug-discovery platform, using orthotopic transplant animal models and clinical translational research to identify anticancer targets, with a focus on pancreatic and ovarian cancer indications. The South Korean company co-develops new drugs with domestic and international biotech partners.

1 investor

Kolon TissueGene develops cell and gene therapies targeting musculoskeletal diseases and degenerative disorders. The company has built a proprietary platform over 20 years and aims to bring safe and effective treatments to improve pain and function for patients.

1 investor